Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Intra-Cellular Therapies Q4 EPS $(0.16) Misses $(0.11) Estimate, Sales $199.22M Beat $193.40M Estimate

Author: Benzinga Newsdesk | February 21, 2025 08:39am
Intra-Cellular Therapies (NASDAQ:ITCI) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.11) by 45.45 percent. This is a 44.83 percent increase over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $199.22 million which beat the analyst consensus estimate of $193.40 million by 3.01 percent. This is a 50.81 percent increase over sales of $132.10 million the same period last year.

Posted In: ITCI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist